PATENT CLAIM ANALYSIS

Application Number: 15977626
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "001300"]

Abstract:
The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.

Claim (Index 30):
A conjugate having a formula\n B-L-(D) n  or a pharmaceutically acceptable salt thereof;\n wherein B is a radical of a PSMA binding ligand; \n wherein L is a polyvalent linker comprising a polyether portion; \n wherein D is a therapeutic agent or a radioactive isotope of a metal coordinated to a chelating group; and \n wherein n is 1.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 93.0
- Lexical Diversity: 1.72727
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14443212', '15245505', '12673931', '14794482', '15959110']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7069920660977186
- 35 USC 102 Novelty (BERT): 0.5403459856347747
- Combined Prediction Score: 0.6903274580514243
- Mean Citation Score: 302.8010000000001
- Max Citation Score: 389.53864
- Similarity Product: 278.935725173459

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test